GLP-1s for Men Over 50: Testosterone, Visceral Fat, and Metabolic Health

Walk into any conversation about GLP-1 medications — semaglutide, tirzepatide, liraglutide — and you might get the impression these drugs are primarily for women. The marketing images skew female. The social media discussions skew female. Even the word “Ozempic” has acquired a distinctly feminine cultural connotation. Meanwhile, millions of men over 50 are silently struggling with the very problem GLP-1s are best at solving: accumulating visceral belly fat that responds poorly to diet and exercise alone, declining energy and testosterone, and worsening metabolic markers despite their best efforts.

The science does not support the gendered narrative. GLP-1 medications work powerfully in men, and the mechanisms are particularly well-matched to the hormonal and metabolic changes that hit men in midlife. This article addresses the most common myths head-on and gives men over 50 the evidence-based information they deserve.

What Happens to Men’s Metabolism After 50

After 50, men experience a constellation of metabolic changes that closely parallel — though differ in mechanism from — those experienced by menopausal women. The key drivers include:

• Declining testosterone: Total testosterone declines approximately 1–2% per year after age 30, with free testosterone falling faster due to rising sex hormone-binding globulin (SHBG). By their mid-50s, many men have total testosterone in the low-normal or frankly low range.
• Rising visceral adiposity: Visceral fat accumulation is both a consequence and a cause of low testosterone — a vicious cycle. Adipose tissue contains aromatase, the enzyme that converts testosterone to estradiol, further suppressing T levels.
• Insulin resistance: Excess visceral fat promotes insulin resistance, which in turn impairs glucose metabolism and accelerates further fat storage.
• Loss of lean mass: Sarcopenia (age-related muscle loss) accelerates after 50, reducing metabolic rate and insulin sensitivity.

This is the metabolic landscape GLP-1 medications are entering when prescribed to men over 50. And understanding it makes the clinical trial data considerably more interpretable. For men in Savannah, Pooler, or Hinesville exploring medical weight loss options, this biological context is where the conversation needs to start.

Myth #1: GLP-1 Medications Are “For Women”

This myth has no scientific basis. GLP-1 receptors are not sex-specific. The physiological mechanisms by which GLP-1 agonists reduce appetite, improve insulin sensitivity, slow gastric emptying, and modulate central satiety circuits operate identically in male and female brains and metabolic systems.

The SELECT trial — the landmark semaglutide cardiovascular outcomes trial published in The New England Journal of Medicine in 2023 — enrolled over 17,600 adults with obesity and established cardiovascular disease, approximately 72% of whom were male. The cardiovascular benefits of semaglutide 2.4 mg weekly were observed across both sexes, and male participants showed robust reductions in body weight, waist circumference, and cardiometabolic risk markers.

Subgroup analyses from the STEP program similarly confirm that men achieve clinically meaningful weight loss — typically 12–16% of body weight over 68 weeks on semaglutide 2.4 mg — that is statistically comparable to female participants. Tirzepatide (SURMOUNT-1) showed even larger weight losses in male subgroups in some analyses, with men achieving up to 20%+ body weight reduction.

The gendered perception of GLP-1 medications is a cultural artifact, not a pharmacological reality.

Myth #2: Testosterone Replacement Is the Answer to Midlife Belly Fat

This is one of the most consequential myths in men’s health, because it leads many men to pursue testosterone replacement therapy (TRT) as a primary weight-management strategy when TRT alone rarely produces meaningful fat loss — and in some cases makes metabolic management more complicated.

The relationship between testosterone and body composition is real but operates largely in the opposite direction than most men assume: it is excess visceral fat that suppresses testosterone, not (primarily) low testosterone that causes visceral fat accumulation.

Multiple studies, including a well-cited analysis in The Journal of Clinical Endocrinology & Metabolism, have demonstrated that weight loss — regardless of method — produces significant and sustained increases in endogenous testosterone. The mechanism is well understood: visceral fat contains high levels of aromatase activity, converting testosterone to estradiol. Reducing visceral fat reduces aromatase-driven T suppression, and circulating testosterone rises naturally.

Across GLP-1 clinical trials, men who lost significant weight consistently showed meaningful improvements in total and free testosterone. In one observational study of obese men treated with semaglutide, testosterone levels rose by a clinically meaningful margin after 12–24 weeks — parallel to the degree of abdominal fat loss — without any exogenous testosterone administration.

This has important clinical implications. Men who pursue TRT before addressing visceral obesity are treating a downstream consequence while leaving the primary driver intact. Worse, exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis, which can complicate natural testosterone recovery and requires ongoing management of hematocrit and other parameters. GLP-1-mediated weight loss, which restores T naturally by reducing aromatase burden, is in many cases a safer and more sustainable first-line strategy for men whose low testosterone is primarily weight-driven.

Experienced bariatric physicians like Dr. Donald L. Gates at Scale Solutions routinely assess testosterone status as part of a comprehensive metabolic evaluation — and sequence treatment decisions accordingly.

Myth #3: GLP-1 Medications Harm Testosterone Levels

This fear — that semaglutide or tirzepatide might suppress testosterone or impair male reproductive hormones — is not supported by the clinical evidence.

No mechanism exists by which GLP-1 receptor agonism would directly suppress the hypothalamic-pituitary-gonadal (HPG) axis. GLP-1 receptors are expressed in multiple tissues including the brain, pancreas, gut, and heart — but their activation does not negatively interact with luteinizing hormone (LH), follicle-stimulating hormone (FSH), or testosterone biosynthesis in the testes.

What the data actually show is a net positive effect on male reproductive hormones via weight loss. SELECT trial secondary analyses confirmed no adverse signal on reproductive hormone endpoints in male participants. Post-hoc analyses of STEP trials found testosterone levels in male participants either unchanged or improved relative to baseline, consistent with the weight-loss-mediated aromatase reduction described above.

For men specifically concerned about this question — particularly those already on TRT who are considering adding a GLP-1 medication — the answer from available evidence is reassuring: GLP-1 therapy does not suppress testosterone and is likely to improve the natural testosterone environment by reducing visceral fat and its associated aromatase activity.

GLP-1s and Visceral Fat: Why This Matters Most for Men Over 50

Visceral adipose tissue (VAT) is the primary metabolic villain in male midlife health. Unlike subcutaneous fat, VAT:

• Releases free fatty acids directly into the portal circulation, driving hepatic insulin resistance
• Secretes pro-inflammatory adipokines (IL-6, TNF-alpha, leptin) that promote systemic inflammation
• Contains dense aromatase activity that suppresses testosterone
• Correlates more strongly with cardiovascular risk than overall BMI

GLP-1 medications are particularly effective at reducing VAT. Imaging substudies from the STEP and SURMOUNT programs using MRI and CT volumetric measurements consistently show that semaglutide and tirzepatide reduce visceral fat disproportionately relative to total body weight loss — a finding directly relevant to men whose metabolic risk is concentrated in abdominal adiposity.

In the SELECT trial, men who lost the most weight on semaglutide showed the largest reductions in waist circumference (a VAT proxy), with corresponding improvements in fasting glucose, triglycerides, HDL cholesterol, and blood pressure. This cardiometabolic risk-factor improvement is the reason the SELECT trial found a 20% reduction in major adverse cardiovascular events (MACE) in the semaglutide group — a finding with profound implications for men over 50, who face disproportionately high cardiovascular event rates. You can explore more about GLP-1 cardiovascular evidence at our coastal Georgia GLP-1 resource hub.

Practical Guidance for Men Over 50 Considering GLP-1 Therapy

• Get a baseline metabolic panel: Fasting glucose, HbA1c, fasting lipids, liver enzymes, and total/free testosterone should all be assessed before starting therapy
• Prioritize resistance training: GLP-1 medications reduce appetite, which can accelerate lean mass loss. Resistance training 3–4 times per week and protein intake of 1.2–1.6 g/kg body weight per day are essential to preserve muscle
• Don’t rush to TRT: If testosterone is low but weight is high, optimize weight first. Many men see T normalize to adequate levels with meaningful visceral fat reduction alone
• Set realistic waist circumference goals: Waist circumference below 40 inches is the metabolic threshold target for men. Track this alongside scale weight
• Monitor cardiovascular risk markers: Blood pressure, LDL, triglycerides, and hsCRP should be tracked to confirm the metabolic benefits that the clinical trials demonstrate

The Verdict: GLP-1s Are a Legitimate Men’s Health Tool

The evidence is unambiguous. GLP-1 receptor agonists are as effective for men as for women, and the metabolic benefits — particularly visceral fat reduction and natural testosterone restoration — are especially relevant to men over 50. The cardiovascular outcomes data from SELECT, which enrolled a predominantly male cohort, establish GLP-1 therapy as a meaningful life-extension intervention for men at high cardiometabolic risk.

If you are a man over 50 who has been told GLP-1s aren’t for you, or who has been chasing testosterone optimization without addressing visceral fat, the science suggests it is time to reconsider. With a physician who understands the male metabolic profile in depth, GLP-1 therapy can be one of the most impactful health investments available.

Take Control of Your Metabolic Health

When it comes to GLP-1 medications, who prescribes and where the medication comes from matters enormously. Get GLP-1 treatment from a physician you trust, working with licensed, state-board-accredited compounding pharmacies and FDA-approved brand-name medications. Dr. Donald L. Gates has practiced bariatric medicine since 1999 and personally oversees every patient at Scale Solutions — only sourcing from licensed, accredited pharmacies. Serving Savannah, Pooler, and Hinesville, GA. Call (912) 352-7546 or book a consultation today.

Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice. Testosterone management and GLP-1 therapy should be evaluated individually by a licensed physician. Do not alter existing testosterone replacement therapy without consulting your prescribing clinician.

Frequently Asked Questions

Do GLP-1 medications like semaglutide work for men trying to lose belly fat?

Yes. GLP-1 medications are highly effective for visceral fat reduction in men. SELECT trial data — which enrolled over 12,000 male participants — confirm robust reductions in waist circumference, body weight, and cardiometabolic risk markers. Male subgroups in STEP and SURMOUNT trials showed weight losses of 12–22% over treatment periods.

Will losing weight on a GLP-1 improve my testosterone levels?

Likely yes, especially if your testosterone is low due to obesity-related aromatase activity in visceral fat. Multiple studies show that significant weight loss raises total and free testosterone in men, often into the normal range without exogenous testosterone supplementation. This effect is proportionate to the degree of visceral fat lost.

Should I try testosterone replacement before GLP-1 therapy if I have low T and belly fat?

Not necessarily. If visceral obesity is the primary driver of your low testosterone — which is common — addressing the obesity first with GLP-1 therapy may normalize testosterone naturally. Starting TRT before optimizing weight leaves the primary cause of T suppression (aromatase activity in visceral fat) unaddressed and creates ongoing hormonal management complexity.

Can I take GLP-1 medications if I am already on testosterone replacement?

In most cases, yes. GLP-1 receptor agonists do not pharmacologically interact with the HPG axis and will not suppress your exogenous testosterone. Your physician should monitor both your weight-loss progress and your testosterone levels to determine whether TRT dose adjustments become appropriate as visceral fat decreases.

Are the cardiovascular benefits of GLP-1s proven for men?

Yes. The SELECT trial, which was predominantly male, demonstrated a 20% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in the semaglutide group versus placebo. This is the most powerful cardiovascular outcomes evidence to date for a weight-loss medication, and it was generated largely in a male population.